Welcome to our dedicated page for Avinger news (Ticker: AVGR), a resource for investors and traders seeking the latest updates and insights on Avinger stock.
Avinger Inc (AVGR) is a pioneer in image-guided therapies for vascular disease, developing catheter-based systems that integrate real-time imaging with precision treatment. This page serves as the definitive source for verified news and official updates about the company’s medical device innovations and market developments.
Investors and healthcare professionals will find timely information on product launches, clinical trial results, and strategic partnerships related to Avinger’s Lumivascular platform. The curated collection includes updates on FDA clearances, technology advancements in OCT-guided procedures, and progress in treating peripheral artery disease.
Content spans regulatory milestones, financial disclosures, and research collaborations that impact Avinger’s position in the $5B+ vascular intervention market. All materials are sourced from official releases to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to essential AVGR developments. Check regularly for updates on next-generation atherectomy devices and emerging applications in coronary artery disease treatment.
Avinger, Inc. (NASDAQ:AVGR) has received 510(k) clearance from the FDA for its Pantheris system, allowing it to treat in-stent restenosis (ISR)real-time intravascular imaging combined with precise control to effectively target ISR lesions. The opportunity in this market is significant, as an estimated 30-40% of stents face restenosis within three years after placement.
Avinger, Inc. (NASDAQ: AVGR) reported a revenue of $2.4 million for Q3 2021, reflecting a 3% increase year-over-year. The gross margin remained steady at 34%. The company opened 8 new Lumivascular accounts despite challenges from COVID-19. Avinger announced a 510(k) submission to expand Pantheris' indications to include treatment of in-stent restenosis and a new Lightbox 3 imaging console. Operating expenses rose to $5.3 million, leading to a net loss of $6.0 million. Cash reserves stood at $23.1 million as of September 30, 2021.
Avinger, Inc. (NASDAQ:AVGR), a medical device company, is set to release its third quarter 2021 financial results on November 11, 2021, after market close. A conference call will follow at 1:30 pm PT / 4:30 pm ET, accessible via phone or live webcast on the company’s investor relations page. Avinger specializes in intravascular imaging systems for diagnosing and treating Peripheral Artery Disease (PAD), which impacts millions globally. The company aims to transform vascular disease treatment through its Lumivascular platform.
Avinger has announced positive results from its INSIGHT study for the Pantheris system, aimed at treating in-stent restenosis (ISR) in lower extremity arteries. Presented at the VIVA conference, the study followed 85 patients, showing an 82% luminal gain post-procedure, with 93% freedom from target lesion restenosis at 6 months and 89% at 12 months. Notably, there were no amputations reported. The results support a pending FDA 510(k) submission for an ISR indication. With ISR affecting up to 40% of stents placed annually, the data position Pantheris as a potential frontline therapy.
Avinger, Inc. (NASDAQ:AVGR), a medical device company, will engage in investor meetings from September 13-15, 2021, at the H.C. Wainwright 23rd Annual Global Investment Conference. The company specializes in the diagnosis and treatment of Peripheral Artery Disease (PAD), which impacts over 12 million people in the U.S. and 200 million globally. Avinger is known for its innovative Lumivascular platform, including its imaging console and catheter systems. Interested investors can contact H.C. Wainwright for scheduling inquiries.
Avinger, Inc. (NASDAQ:AVGR) presented its Lumivascular, OCT-guided technologies at the AMP conference, focusing on critical limb ischemia treatment. Dr. Jaafer Golzar shared insights on Avinger’s Pantheris SV and Tigereye catheters, emphasizing ongoing clinical trials that could enhance their efficacy in treating Peripheral Artery Disease (PAD). CEO Jeff Soinski highlighted the growing acceptance of their technologies in the medical community. Avinger aims to transform PAD treatment, impacting over 12 million patients in the U.S. alone.
Avinger reported a 91% year-over-year revenue growth for Q2 2021, reaching $2.8 million, driven by strong Pantheris and Tigereye sales. The Pantheris SV revenue increased significantly due to market adoption in below-the-knee treatments, while image-guided CTO revenue surged 114% following the Tigereye launch at over 40 sites. The gross margin improved to 36%, and the company maintains a robust cash position of $26.7 million, expected to support future growth through 2022.
Avinger (NASDAQ:AVGR) announced the submission of a 510(k) application to the FDA for its new Lightbox 3 imaging console, which aims to revolutionize the treatment of Peripheral Artery Disease (PAD)
The new console features significant reductions in size and weight, improving portability and user experience, while enhancing imaging capabilities. President & CEO Jeff Soinski highlighted the potential of Lightbox 3 to accelerate new account acquisition and enhance existing user engagements. The console embodies Avinger's commitment to advancing medical imaging technology, which could lead to improved outcomes for PAD patients.
Avinger, Inc. (Nasdaq:AVGR), a medical device company, will release its Q2 2021 financial results on August 10, 2021, after market close. The company offers the first intravascular image-guided system for treating Peripheral Artery Disease (PAD), impacting over 12 million people in the U.S. A conference call will be held at 1:30 PM PT / 4:30 PM ET, which can be accessed via phone or webcast. A replay will also be available on Avinger's website.
Avinger, Inc. (NASDAQ:AVGR) has submitted a 510(k) application to the FDA for a new clinical indication of its Pantheris system to treat in-stent restenosis (ISR) in lower extremity arteries. The application is supported by data from the INSIGHT trial, highlighting the device's safety and efficacy. With 200,000 stents placed annually, 30%-40% of which may develop ISR, this presents a significant market opportunity. The Pantheris system offers advantages over existing treatments by enabling targeted blockage removal while minimizing risks associated with stent damage, potentially improving patient outcomes.
FAQ
What is the current stock price of Avinger (AVGR)?
What is the market cap of Avinger (AVGR)?
